Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib-Reference-Cited by-同舟云学术

Reversal of CD8 T-Cell–Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib

Published:2014-04 Issue:4 Volume:134 Page:992-1000
ISSN:0022-202X
Container-title:Journal of Investigative Dermatology
language:en
Short-container-title:Journal of Investigative Dermatology

Author:

Okiyama Naoko,Furumoto Yasuko,Villarroel Vadim A.,Linton Jay T.,Tsai Wanxia L.,Gutermuth Jan,Ghoreschi Kamran,Gadina Massimo,O'Shea John J.,Katz Stephen I.

Publisher

Elsevier BV

Subject

Cell Biology,Dermatology,Molecular Biology,Biochemistry

Reference39 articles.

1. Advances in graft-versus-host disease biology and therapy;Blazar;Nat Rev Immunol,2012

2. Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis;Boy;J Invest Dermatol,2009

3. Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease;Chen;Blood,2007

4. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new;Coghill;Blood,2011

5. The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing;Conklyn;J Leukoc Biol,2004

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The JAK-STAT pathway: from structural biology to cytokine engineering;Signal Transduction and Targeted Therapy;2024-08-21

2. The application of JAK inhibitors in the peri-transplantation period of hematopoietic stem cell transplantation for myelofibrosis;Annals of Hematology;2024-03-18

3. Dissecting the regulatory network of transcription factors in T cell phenotype/functioning during GVHD and GVT;Frontiers in Immunology;2023-06-27

4. Potential Use of Janus Kinase Inhibitors in the Treatment of Systemic Lupus Erythematosus;Journal of Inflammation Research;2023-04

5. Tofacitinib combined with melanocyte protector α-MSH to treat vitiligo through dextran based hydrogel microneedles;Carbohydrate Polymers;2023-04